Roche Holding AG
SIX:RO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
247.2
356.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
|
| DE |
|
Bayer AG
XETRA:BAYN
|
40.8B EUR |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
Market Distribution
| Min | -62 472.2% |
| 30th Percentile | 4.5% |
| Median | 11.2% |
| 70th Percentile | 17.1% |
| Max | 91.2% |
Other Profitability Ratios
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Roche Holding AG is 33.8%, which is above its 3-year median of 32.2%.
Over the last 3 years, Roche Holding AG’s Operating Margin has increased from 31.4% to 33.8%. During this period, it reached a low of 31.2% on Jun 30, 2023 and a high of 33.8% on Jun 30, 2025.